AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37079894 — intervention group
Group type: COMPARATOR
Intervention: Bismuth quadruple therapy (esomeprazole 20 mg, bismuth 220 mg twice a day, metronidazole 400 mg, tetracycline 500 mg 4 times a day)
Number of subjects: 364
Study 37079900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-based PrEP delivery model
Number of subjects: 287
Study 37079900 — intervention group
Group type: COMPARATOR
Intervention: Standardized client actors (mystery shoppers)
Number of subjects: 287
Study 37080000 — intervention group
Group type: EXPERIMENTAL
Intervention: Single RBC (1-RBC arm)
Number of subjects: 245
Study 37080000 — intervention group
Group type: COMPARATOR
Intervention: Double RBC (2-RBC arm)
Number of subjects: 245
Study 37080222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Number of subjects: 649
Study 37080222 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 649
Study 37080223 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (carboplatin and paclitaxel) after standard cisplatin-based chemoradiotherapy
Number of subjects: 926
Study 37080223 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy only
Number of subjects: 926
Study 37080223 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (carboplatin and paclitaxel)
Number of subjects: 926
Study 37080224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertussis vaccination in group 1 (≤23 weeks + 6 days)
Number of subjects: 364
Study 37080224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertussis vaccination in group 2 (24-27 weeks + 6 days)
Number of subjects: 364
Study 37080224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertussis vaccination in group 3 (28-31 weeks + 6 days)
Number of subjects: 364
Study 37080224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertussis vaccination in all groups
Number of subjects: 364
Study 37080296 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity restriction (pelvic rest, prohibition of sexual activity, reduction of work and/or nonwork activity)
Number of subjects: 120
Study 37080296 — intervention group
Group type: COMPARATOR
Intervention: No activity restriction (control group)
Number of subjects: 120
Study 37080296 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity restriction
Number of subjects: 120
Study 37080354 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline plus smoke-free homes intervention
Number of subjects: 0
Study 37080354 — intervention group
Group type: COMPARATOR
Intervention: Standard quitline
Number of subjects: 0
Study 37080442 — intervention group
Group type: EXPERIMENTAL
Intervention: FB-EVAR
Number of subjects: 506
Study 37080442 — intervention group
Group type: EXPERIMENTAL
Intervention: FB-EVAR (Group 1 - prior EVAR)
Number of subjects: 506
Study 37080442 — intervention group
Group type: EXPERIMENTAL
Intervention: FB-EVAR (Group 2 - prior abdominal OSR)
Number of subjects: 506
Study 37080442 — intervention group
Group type: COMPARATOR
Intervention: FB-EVAR (Controls - no previous aortic repair)
Number of subjects: 506
Study 37080462 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg PP + CC
Number of subjects: 50
Study 37080462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 37080462 — intervention group
Group type: EXPERIMENTAL
Intervention: PP (doses ≤150 mg)
Number of subjects: 50
Study 37080558 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance elastography-assessed liver stiffness (LS)
Number of subjects: 104
Study 37080558 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-point Dixon-derived proton density fat fraction (PDFF)
Number of subjects: 104
Study 37080558 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-point saturation-recovery acquisition-calculated T1 relaxation time
Number of subjects: 104
Study 37080624 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (baseline samples immediately analysed for total homocysteine)
Number of subjects: 0
Study 37080624 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline samples analysed after 12 months)
Number of subjects: 0
Study 37080623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% atropine eyedrops
Number of subjects: 300
Study 37080623 — intervention group
Group type: COMPARATOR
Intervention: 0.01% atropine
Number of subjects: 300
Study 37080623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% atropine
Number of subjects: 300
Study 37080628 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing for six STIs alongside routine HIV and syphilis testing.
Number of subjects: 1000
Study 37080629 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 200
Study 37080829 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose MVC-COV1901
Number of subjects: 803
Study 37080829 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose MVC-COV1901
Number of subjects: 803
Study 37080829 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222
Number of subjects: 803
Study 37080829 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose mRNA-1273
Number of subjects: 803
Study 37080829 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous boosting (mRNA-1273 in MVC-COV1901 primed individuals)
Number of subjects: 803
Study 37080829 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-COV1901 as a primary series with either homologous or heterologous booster
Number of subjects: 803
Study 37080942 — intervention group
Group type: EXPERIMENTAL
Intervention: E7130 administered intravenously at 480 μg/m (Q3W)
Number of subjects: 44
Study 37080942 — intervention group
Group type: EXPERIMENTAL
Intervention: E7130 administered intravenously at 480 μg/m (Q2W)
Number of subjects: 44
Study 37080942 — intervention group
Group type: EXPERIMENTAL
Intervention: E7130 (both Q3W and Q2W)
Number of subjects: 44
Study 37080946 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in KRT decision-making
Number of subjects: 56
Study 37080946 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on KRT and decision aids for relatives/friends
Number of subjects: 56
Study 37081029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil and evening primrose oil (EPO) supplementation (2 gel capsules of fish oil and 3 gel capsules of EPO for 12 weeks)
Number of subjects: 32
Study 37081029 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil (placebo, 5 gel capsules of 1g for 12 weeks)
Number of subjects: 32
Study 37081029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil and evening primrose oil (EPO) supplementation
Number of subjects: 32
Study 37081029 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil (placebo)
Number of subjects: 32
Study 37081046 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab/infliximab with standard treatment
Number of subjects: 153
Study 37081046 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab with standard treatment
Number of subjects: 153
Study 37081046 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 153
Study 37081093 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP-COVID intervention (six-session mentalization-based prenatal group program offered online)
Number of subjects: 100
Study 37081093 — intervention group
Group type: COMPARATOR
Intervention: Natural trajectory of prenatal care (control)
Number of subjects: 100
Study 37081093 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP-COVID intervention
Number of subjects: 100
Study 37081278 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised purified flavonoid fraction
Number of subjects: 6000
Study 37081406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Neurophysiological Rehabilitation System (INRS) treatment
Number of subjects: 48
Study 37081406 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list for 4 weeks, then INRS treatment)
Number of subjects: 48
Study 37081406 — intervention group
Group type: EXPERIMENTAL
Intervention: INRS treatment
Number of subjects: 48
Study 37081426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Lutetium-177 PSMA Radioligand Therapy (RLT) followed by one fraction of HDR brachytherapy
Number of subjects: 30
Study 37081426 — intervention group
Group type: COMPARATOR
Intervention: High dose rate (HDR) brachytherapy in two fractions (standard of care salvage treatment)
Number of subjects: 30
Study 37081426 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutetium-177 PSMA RLT and HDR brachytherapy
Number of subjects: 30
Study 37081460 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Living Every Day (ALED) intervention
Number of subjects: 336
Study 37081460 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise sessions, facility access, Fitbit self-monitoring
Number of subjects: 336
Study 37081460 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions combined
Number of subjects: 336
Study 37081459 — intervention group
Group type: EXPERIMENTAL
Intervention: RBS after AGB (types included sleeve gastrectomies, Roux-en Y gastric by-passes, one anastomosis gastric by-passes)
Number of subjects: 234
Study 37081459 — intervention group
Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 234
Study 37081459 — intervention group
Group type: EXPERIMENTAL
Intervention: SG
Number of subjects: 234
Study 37081459 — intervention group
Group type: EXPERIMENTAL
Intervention: RBS after AGB
Number of subjects: 234
Study 37081474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical power (MP) on hospital day 1 (HD1)
Number of subjects: 1217
Study 37081474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical power (MP) on hospital day 3 (HD3)
Number of subjects: 1217
Study 37081474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical power (MP) on hospital day 7 (HD7)
Number of subjects: 1217
Study 37081523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneuploidy in Circulating Tumour DNA (ACT-Discover) method using haplotype phasing of paired tumour biopsies or PDXs
Number of subjects: 24
Study 37081523 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-derived xenograft (PDX) tumours
Number of subjects: 24
Study 37081523 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-Discover method
Number of subjects: 24
Study 37081524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed oil (MO) lipid emulsion
Number of subjects: 60
Study 37081524 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (SO) lipid emulsion
Number of subjects: 60
Study 37081528 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional neural network classifier for Alzheimer's disease detection
Number of subjects: 432
Study 37081534 — intervention group
Group type: EXPERIMENTAL
Intervention: Suubi intervention components (Financial Literacy Training, incentivized matched Youth Savings Accounts, manualized ART adherence intervention, engagement with role models)
Number of subjects: 576
Study 37081534 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Suubi intervention components
Number of subjects: 576
Study 37081534 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments at baseline, 12, 24, 36, and 48 months post-intervention initiation
Number of subjects: 576
Study 37081574 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg once weekly
Number of subjects: 255
Study 37081574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 37081617 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 2424
Study 37081617 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced eGFR
Number of subjects: 2424
Study 37081617 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated urinary albumin-to-creatinine ratio
Number of subjects: 2424
Study 37081617 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2424
Study 37081617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2424
Study 37081617 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended treatment (ACE inhibitors, ARBs)
Number of subjects: 2424
Study 37081722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib (400 mg)
Number of subjects: 25
Study 37081722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus docetaxel (60 mg)
Number of subjects: 25
Study 37082098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks (Q3W)
Number of subjects: 563
Study 37082098 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (platinum-doublet)
Number of subjects: 563
Study 37082579 — intervention group
Group type: EXPERIMENTAL
Intervention: TRK-950 (therapeutic humanized anti-CAPRIN-1 antibody)
Number of subjects: 0
Study 37082579 — intervention group
Group type: EXPERIMENTAL
Intervention: TRK-950
Number of subjects: 0
Study 37082807 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 20000
Study 37082807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20000
Study 37082935 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1)
Number of subjects: 0
Study 37082935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37082967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nerinetide
Number of subjects: 1092
Study 37083029 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered care (PCC) intervention for inpatient staff
Number of subjects: 0
Study 37083300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral mastectomy (BMX)
Number of subjects: 123
Study 37083300 — intervention group
Group type: COMPARATOR
Intervention: Non-BMX treatments
Number of subjects: 123
Study 37083300 — intervention group
Group type: EXPERIMENTAL
Intervention: BC patients
Number of subjects: 123
Study 37083300 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 123
Study 37083317 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive CHW delivery (door-to-door home visits)
Number of subjects: 137
Study 37083317 — intervention group
Group type: COMPARATOR
Intervention: Passive CHW delivery (fixed village site)
Number of subjects: 137
Study 37083360 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel kit formulation targeting fibroblast activation protein (FAP)
Number of subjects: 0
Study 37083403 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut Microbiota
Number of subjects: 0
Study 37083403 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Metabolites
Number of subjects: 0
Study 37083461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed nuts (42g daily)
Number of subjects: 20
Study 37083461 — intervention group
Group type: COMPARATOR
Intervention: Potato chips (46g daily)
Number of subjects: 20
Study 37083464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV)
Number of subjects: 400
Study 37083464 — intervention group
Group type: EXPERIMENTAL
Intervention: Client Violence
Number of subjects: 400
Study 37083664 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (0.25 mg/kg intravenous injection)
Number of subjects: 903
Study 37083664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903
Study 37083664 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 903
Study 37083664 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine and Placebo
Number of subjects: 903
Study 37083700 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based, peer-led sexual and reproductive health services (Yathu Yathu intervention)
Number of subjects: 1989
Study 37083700 — intervention group
Group type: COMPARATOR
Intervention: Control arm (health facility only)
Number of subjects: 1989
Study 37083738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoserratus plane block (PSPB)
Number of subjects: 60
Study 37083738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study 37083754 — intervention group
Group type: EXPERIMENTAL
Intervention: MedViewer test
Number of subjects: 36
Study 37084097 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive breaks (2.5-min standing rest)
Number of subjects: 21
Study 37084097 — intervention group
Group type: EXPERIMENTAL
Intervention: Active breaks (2.5-min targeted stretching and mobilization exercises)
Number of subjects: 21
Study 37084097 — intervention group
Group type: COMPARATOR
Intervention: No breaks (control condition)
Number of subjects: 21
Study 37084104 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Friendship Bench (EFB) intervention
Number of subjects: 80
Study 37084104 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 37084132 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 15
Study 37084140 — intervention group
Group type: EXPERIMENTAL
Intervention: eEF2 (elongation factor-2) as a biomarker
Number of subjects: 40
Study 37084140 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic analysis
Number of subjects: 40
Study 37084140 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory mechanisms of eEF2
Number of subjects: 40
Study 37084261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal oxytocin, 100 µg
Number of subjects: 5
Study 37084261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 5
Study 37084329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 37084329 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 0
Study 37084342 — intervention group
Group type: EXPERIMENTAL
Intervention: Elafibranor 120 mg daily for 12 weeks
Number of subjects: 10
Study 37084342 — intervention group
Group type: EXPERIMENTAL
Intervention: Elafibranor 80 mg daily for 12 weeks
Number of subjects: 10
Study 37084383 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical BMT with posttransplantation cyclophosphamide (PTCy) and 400 cGy total body irradiation
Number of subjects: 27
Study 37084383 — intervention group
Group type: COMPARATOR
Intervention: Lower dose total body irradiation (200 cGy)
Number of subjects: 27
Study 37084383 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical BMT with PTCy
Number of subjects: 27
Study 37084401 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 61
Study 37084401 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (active vitamin D and phosphate)
Number of subjects: 61
Study 37084590 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, vegan diet including cooked soybeans (1/2 cup [86 g]/day) for 12 weeks
Number of subjects: 84
Study 37084590 — intervention group
Group type: COMPARATOR
Intervention: Usual diet for 12 weeks
Number of subjects: 84
Study 37084629 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR)
Number of subjects: 522
Study 37084629 — intervention group
Group type: EXPERIMENTAL
Intervention: k-nearest neighbor (kNN)
Number of subjects: 522
Study 37084629 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 522
Study 37084629 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiLayer Perceptron (MLP)
Number of subjects: 522
Study 37084629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensemble feature selection
Number of subjects: 522
Study 37084748 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy (54 Gy with a 0.5 cm clinical target volume margin) combined with limited surgery
Number of subjects: 94
Study 37084803 — intervention group
Group type: EXPERIMENTAL
Intervention: AGuIX®-based radiation treatments
Number of subjects: 4
Study 37084814 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D
Number of subjects: 136
Study 37084814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 37085287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 150 mg followed by boluses of 40 mg every 6 hours and infusion of 2 mg/hour
Number of subjects: 15
Study 37085287 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based ropivacaine dosing
Number of subjects: 15
Study 37085328 — intervention group
Group type: EXPERIMENTAL
Intervention: Informant report measured with the Cognitive Difficulties Scale (IMAP+) and Everyday Cognition (ADNI) in patients with mild cognitive impairment (MCI)
Number of subjects: 841
Study 37085328 — intervention group
Group type: COMPARATOR
Intervention: Informant report in cognitively unimpaired older individuals (controls)
Number of subjects: 841
Study 37085328 — intervention group
Group type: EXPERIMENTAL
Intervention: Informant report in patients with subjective cognitive decline (SCD)
Number of subjects: 841
Study 37085328 — intervention group
Group type: EXPERIMENTAL
Intervention: Informant report in patients with Alzheimer-type dementia (AD dementia)
Number of subjects: 841
Study 37085451 — intervention group
Group type: EXPERIMENTAL
Intervention: HepB-CpG (HEPLISAV-B)
Number of subjects: 147
Study 37085451 — intervention group
Group type: COMPARATOR
Intervention: HepB-Eng (Engerix-B)
Number of subjects: 147
Study 37085523 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk-based fortifiers (HMBF)
Number of subjects: 0
Study 37085523 — intervention group
Group type: COMPARATOR
Intervention: Bovine milk-based fortifiers (BMBF)
Number of subjects: 0
Study 37085651 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the Tilburg Frailty Indicator (TFI)
Number of subjects: 457
Study 37085674 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTA1*A*A
Number of subjects: 60
Study 37085674 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTA1*A*B
Number of subjects: 60
Study 37085674 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTA1*B*B
Number of subjects: 60
Study 37085674 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTA1 polymorphism
Number of subjects: 60
Study 37085731 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIM parameters (ADC, D, f) in LVI-positive group
Number of subjects: 90
Study 37085731 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parameter (D + f + thickness)
Number of subjects: 90
Study 37085731 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC, D, f
Number of subjects: 90
Study 37085759 — intervention group
Group type: EXPERIMENTAL
Intervention: TalkingMats
Number of subjects: 0
Study 37085759 — intervention group
Group type: COMPARATOR
Intervention: Usual Conversation Method
Number of subjects: 0